Todd P. Branning's Net Worth
$93.1 Thousand
Who is Todd P. Branning?
Todd P. Branning does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Phathom Pharmaceuticals, Inc., Amneal Pharmaceuticals, Inc., and NeuBase Therapeutics, Inc..
SEC CIK
Todd P. Branning's CIK is 0001765274
Past Insider Trading and Trends
2022 was Todd P. Branning's most active year for acquiring shares with 5 total transactions. Todd P. Branning's most active month to acquire stocks was the month of December. 2020 was Todd P. Branning's most active year for disposing of shares, totalling 2 transactions. Todd P. Branning's most active month to dispose stocks was the month of December. 2022 saw Todd P. Branning paying a total of $51,700.00 for 530,000 shares, this is the most they've acquired in one year. In 2020 Todd P. Branning cashed out on 27,407 shares for a total of $37,505.43, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Phathom Pharmaceuticals, Inc. (PHAT) Snapshot price: $17.55
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 13
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Amneal Pharmaceuticals, Inc. (AMRX) Snapshot price: $8.39
SVP and CFOTodd P. Branning owns 12,785 units of Class A Common Stock which is worth $107,266.15. In the year 2019 Todd P. Branning filed a total of 5 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 27
| |||
Form 4
|
∞
| 12.79K |
$5.13 | -$37,505.43 | 12.79K |
Jan 22
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Nov 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 22
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
NeuBase Therapeutics, Inc. (NBSE) No price found
Chief Financial OfficerTodd P. Branning owns 84,200 units of Common stock. In the year 2022 Todd P. Branning acquired a total of 84,200 shares in NeuBase Therapeutics, Inc. at a cost of $51,700.00.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +180.67% | 54.2K |
—
|
—
| 84.2K |
Mar 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Nov 3
| |||
Form 4
| +50.00% | 10K |
$1.81 | $18,100.00 | 30K |
Mar 18
| |||
Form 4
|
∞
| 20K |
$1.68 | $33,600.00 | 20K |
Mar 16 - Mar 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 10
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||